GSK 4382276A
Alternative Names: Avian influenza vaccine; Flu-mRNA; FLU-SV-mRNA; GSK-4382276; GSK-4382276ALatest Information Update: 22 Sep 2025
At a glance
- Originator CureVac
- Developer CureVac; GSK
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 22 Sep 2025 No development reported - Phase-I for Influenza virus infections (Prevention) in Spain (IM)
- 04 Jun 2025 GlaxoSmithKline completes a phase-IIa trial in Influenza virus infections (Prevention) in USA (IM, Injection) (NCT06431607)
- 28 May 2025 No recent reports of development identified for phase-I development in Influenza-virus-infections(In the elderly, Prevention, In adults) in United Kingdom (IM)